Completing data — refresh the page later to see the latest
1051931-39-5CN1C(=Cc2ccc(S(C)(=O)=O)cc2)C(=O)N=C1N.CS(=O)(=O)OQEJPXTVPNIOEHZ-UHFFFAOYSA-N1051931-39-5DTXSID80693939DescriptionZLJ-6 is a dual inhibitor of COX and 5-lipoxygenase (5-LO) (IC50 = 0.73, 0.31, and 0.99 μM for COX-1, COX-2, and 5-LO, respectively, in whole blood). It reduces carrageenin-induced paw edema (inflammation) in rats and acetic acid-induced abdominal constriction (pain) in mice without causing gastrointestinal ulcers, a common side effect of non-selective COX inhibitors.
UsesZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity[1][1].